Riskpilot← Back to searchSign inGet full accessKINN THERAPEUTICS AS
ASActiveOrg 987221518Laboratoriebygget, 9 Etg Haukeland University Hospital, 5021 BergenResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20046 employees
Revenue 2025
NOK 3M
-37% vs 2024
EBITDA margin
13.1%
-76% vs 2024
Equity ratio
87.5%
Financial strength
Net profit 2025
NOK 384K
-77% vs 2024
| Revenue | NOK 3M | -37% |
| EBITDA | NOK 397K | -76% |
| Net profit | NOK 384K | -77% |
| Total assets | NOK 3M | +15% |
| Equity | NOK 2,6M | +17% |
| Employees | 6 | — |
Legal name
KINN THERAPEUTICS AS
Org number
987221518
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. september 2004
Share capital
NOK 105 207
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder hver for seg.
Company purpose
Kommersiell utvikling av medisinske og cellebiologiske hjelpemidler basert på funksjonell genomikk og alt hva herved står i forbindelse, herunder eierskap i andre selskaper og konsulenttjenester.
Address
Laboratoriebygget, 9 Etg Haukeland University Hospital, 5021 Bergen
Phone
+4748203610
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 072 | 1 620 | 3 159 | 4 858 | 3 040 |
| Staff expenses | −2 467 | −1 938 | −2 793 | −2 183 | −2 178 |
| EBITDA | −1 543 | −677 | 181 | 1 681 | 397 |
| Depreciation & amort. | −97 | −64 | −10 | −0 | −14 |
| EBIT | −1 640 | −741 | 171 | 1 681 | 383 |
| Net financials | −2 | −1 | −24 | 25 | 1 |
| Profit before tax | −1 642 | −743 | 148 | 1 705 | 384 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 642 | −743 | 148 | 1 705 | 384 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 507 | 697 | 1 349 | 2 621 | 3 013 |
| Equity | 1 142 | 399 | 547 | 2 253 | 2 636 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 365 | 298 | 802 | 368 | 377 |
| Total debt | 365 | 298 | 802 | 368 | 377 |
EBITDA margin
13.1%
This company
15.8%
Market median
-17% vs market
20212025
Equity ratio
87.5%
This company
38.2%
Market median
+129% vs market
20212025
Return on equity
14.6%
This company
18.4%
Market median
+21% vs market
20212025
Net profit margin
12.6%
This company
8.1%
Market median
+56% vs market
20212025
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20212025
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MP Chief Executive Officer | Chief Executive Officer | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2021 | |
| Deputy Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KINN THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mihaela-Lucia Popa | Chief Executive Officer | 0 companies |
| Emmet Mccormack | Chairman | 0 companies |
| Bjørn Tore Gjertsen | Deputy Chairman | 0 companies |
| Emmet Matin Mccormack | Chairman | 0 companies |
| Jan Inge Nore | Board of Directors | 0 companies |
| Line Bjørge | Board of Directors | 0 companies |